Repeat Ivermectin Mass Drug Administrations for MALaria control II (RIMDAMAL II): a double-blind cluster randomized trial for integrated control of malaria

重复伊维菌素大规模药物管理用于疟疾控制 II (RIMDAMAL II)：疟疾综合控制的双盲整群随机试验

• 批准号: 9754784
• 负责人: BRIAN David FOY
• 金额: $ 70.43万
• 依托单位: COLORADO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-08-01 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9754784
• 关键词: 10 year old; Adopted; Africa; Age; Agriculture; Alleles; Amodiaquine; Anopheles Genus; Anti-malarial drug resistance; Antimalarials; Antiparasitic Agents; Artemisinins; Beds; Behavioral; Biological Assay; Bite; Blood; Burkina Faso; Cessation of life; Chemistry; Chemoprevention; Child; Childhood; Chloroquine; Clinical; Clinical Trials; Cluster randomized trial; Combined Modality Therapy; Communities; Country; Culicidae; Development; Dose; Double-Blind Method; Drops; Drug Combinations; Drug Kinetics; Drug resistance; Ensure; Entomology; Failure; Filarial Elephantiases; Future; Goals; Health; Human; Incidence; Individual; Infection; Ingestion; Insecticide Resistance; Insecticides; Intervention; Ivermectin; Link; Malaria; Measures; Monitor; Morbidity - disease rate; Mutation; Onchocerciasis; Organism; Parasite Control; Parasite resistance; Parasites; Pharmaceutical Preparations; Physiology; Plasmodium; Population; Predisposition; Pregnant Women; Prevalence; Prevention; Preventive treatment; Pyrimethamine-Sulfadoxine; Randomized Clinical Trials; Recipe; Recording of previous events; Residual state; Resistance; Resistance development; Safety; Seasons; Seminal; Southeastern Asia; Sporozoites; Sulfadoxine-pyrimethamine resistance; Testing; Time; aged; arm; artesunate; authority; base; combat; evidence base; experimental study; feeding; indexing; malaria transmission; mortality; neglected tropical diseases; neuromuscular; novel; optimism; preservation; primary endpoint; primary outcome; programs; pyrethroid; rapid diagnosis; resistance allele; success; survivorship; tool; vector; vector control

Project Summary / Abstract Enhanced malaria control efforts since the turn of the century have resulted in notable reductions in malaria morbidity and mortality. This success has been driven by the widespread distribution of long-lasting insecticide treated nets and targeted indoor residual spraying of insecticides to combat vectors as well as rapid diagnosing and treatment of malaria with artemesisin-based combination therapies, and chemoprevention programs for pregnant women and children. However, malaria control efforts are stagnating because programs targeting both the vector and the parasite are not well integrated, and the efficacy of both is severely threatened by widespread resistance of vectors to currently-approved insecticides and spreading resistance of parasites to currently- approved drugs. We hypothesize that malaria control can be enhanced, and the spread of both insecticide resistance and antimalarial drug resistance can be curtailed, if vector and parasite control efforts are linked using the endectocide ivermectin that can target both organisms with another layer of combination therapy to each. Ivermectin is an antiparasitic drug that is safe and distributed to hundreds of millions of humans each year. It also efficiently kills malaria vectors that blood feed on treated people and strong evidence suggests it also has activity against the sporogonic and exoerythrocytic stages of Plasmodium. We will conduct a cluster randomized clinical trial in Burkina Faso to test whether repeated ivermectin mass drug administrations, integrated into a monthly delivery platform with the standard malaria control measures of seasonal malaria chemoprevention and insectide-treated bed net distribution in the Sahel, will reduce childhood malaria incidence and limit resistance in both mosquitoes and parasites.

项目摘要 /摘要 自世纪之交以来，加强疟疾控制工作已导致疟疾显着降低 发病率和死亡率。这一成功是由长期杀虫剂的广泛分布驱动的 经过处理的网和靶向室内残留杀虫剂以对抗载体以及快速诊断 以及使用基于Artemesis蛋白的组合疗法的疟疾治疗，以及用于化学预防计划 孕妇和儿童。但是，疟疾控制努力正在停滞不前，因为针对两者的程序 矢量和寄生虫没有很好地整合，两者的功效都受到广泛的威胁 向量对当前批准的杀虫剂的耐药性，并将寄生虫的耐药性扩散到当前 批准的药物。我们假设可以增强疟疾控制，并且两种杀虫剂的传播 如果使用媒介和寄生虫控制工作，则可以减少耐药性和抗疟疾耐药性 可以用另一种组合疗法靶向两种生物的端肽依维甲膜蛋白。 伊维菌素是一种抗寄生虫药物，每年是安全的，分布到数亿人类。它 还有效地杀死了疟疾媒介，疟疾载体以接受治疗的人为食，有力的证据表明它也有 对疟原虫的孢子虫和外肉眼阶段的活性。我们将进行一个随机的簇 布基纳法索的临床试验测试是否重复伊维菌素群众药物管理，集成到 每月交付平台，具有标准的疟疾控制措施的季节性疟疾化学预防和 经杀虫剂处理的床网分布在萨赫勒地区，将降低儿童疟疾的发病率并限制抗药性 在蚊子和寄生虫中。